Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo

Neuropeptides

Volumn 43, Issue 3, 2009, Pages 235-249

  Śmiałowska, Maria ^a   Domin, Helena ^a   Zieba, Barbara ^a   Koźniewska, Ewa ^b   Michalik, Radosław ^b,c   Piotrowski, Piotr ^b   Kajta, Małgorzata ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Apoptosis; Hippocampus excitotoxicity; Kainic acid; Middle cerebral artery occlusion; Neuroprotection; NPY; NPY receptors; Primary neuronal cultures

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; CASPASE 3; CGP 71683; HUMAN PANCREAS POLYPEPTIDE[CANINE PANCREAS POLYPEPTIDE[1-17], NEUROPEPTIDE Y [19-23],31 ALANINE,32 AMINOISOBUTYRIC ACID,34 GLUTAMINE]; KAINIC ACID; LACTATE DEHYDROGENASE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y [13-36]; NEUROPEPTIDE Y [31 LEUCINE 34 PROLINE]; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN SLICE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG RECEPTOR BINDING; EMBRYO; EXCITOTOXICITY; FEMALE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; INTRAHIPPOCAMPAL DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; TREATMENT RESPONSE;

ANIMALS; CELLS, CULTURED; EXCITATORY AMINO ACID AGONISTS; HIPPOCAMPUS; KAINIC ACID; LIGANDS; MALE; MICE; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y;

EID: 67349261064     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.02.002     Document Type: Article

References (81)

1. Aakerlund L., Gether U., Fuhlendorff J., Schwartz T.W., and Thastrup O. Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett. 260 1 (1990) 73-78
2. Abe K., Tilan J.U., and Zukowska Z. NPY and NPY receptors in vascular remodeling. Curr. Top. Med. Chem. 7 17 (2007) 1704-1709 Review
3. Abounader R., Elhusseiny A., Cohen Z., Olivier A., Stanimirovic D., Quirion R., and Hamel E. Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture. J. Cerebr. Blood Flow Metab. 19 2 (1999) 155-163
4. Abounader R., Villemure J.G., and Hamel E. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226. Br. J. Pharmacol. 116 4 (1995) 2245-2250
5. Aguirre J.A., Fuxe K., Agnati L.F., and von Euler G. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat. Neurosci. Lett. 118 1 (1990) 5-8
6. Baraban S.C. Antiepileptic actions of neuropeptide Y in the mouse hippocampus require Y5 receptors. Epilepsia 43 (2002) 9-13
7. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., and Bartkowski H.M. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17 6 (1986) 1304-1308
8. Bellmann R., Widmann R., Olenik C., Meyer D.K., Maas D., Marksteiner J., and Sperk G. Enhanced rate of expression and biosynthesis of neuropeptide Y after kainic acid-induced seizures. J. Neurochem. 56 2 (1991) 525-530
9. Bendotti C., Vezzani A., Serafini R., Servadio A., Rivolta R., and Samanin R. Increased preproneuropeptide Y mRNA in the rat hippocampus during the development of hippocampal kindling: comparison with the expression of preprosomatostatin mRNA. Neurosci. Lett. 132 2 (1991) 175-178
10. Bijak M. Neuropeptide Y suppresses epileptiform activity in rat frontal cortex and hippocampus in vitro via different NPY receptor subtypes. Neurosci. Lett. 268 3 (1999) 115-118
11. Bijak M., and Śmiałowska M. Effects of neuropeptide Y evoked potentials in the CA1 region and the dentate gyrus of the rat hippocampal slice. Pol. J. Pharmacol. 47 (1995) 333-338
12. Bitran M., Tapia W., Eugenín E., Orio P., and Boric M.P. Neuropeptide Y induced inhibition of noradrenaline release in rat hypothalamus: role of receptor subtype and nitric oxide. Brain Res. 851 1-2 (1999) 87-93
13. Brewer G.J. Serum-free B27/neurobasal medium supports differentiated growth of neurones from the striatum, substantia nigra, septum, cerebral cortex, cerebellum and dentate gyrus. J. Neurosci. Res. 42 (1995) 674-683
14. Cabrele C., Langer M., Bader R., Wieland H.A., Doods H.N., Zerbe O., and Beck-Sickinger A.G. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J. Biol. Chem. 275 46 (2000) 36043-36048
15. Chen S.H., and Cheung R.T. Peripheral and central administration of neuropeptide Y in a rat middle cerebral artery occlusion stroke model reduces cerebral blood flow and increases infarct volume. Brain Res. 927 2 (2002) 138-143
16. Chen S.H., and Cheung R.T. Neuropeptide Y-Y1 receptor agonist worsens while antagonist improves survival of cultured Y1-expressing neuronal cells following oxygen and glucose deprivation. J. Biomed. Sci. 11 6 (2004) 781-788
17. Chen S.H., and Cheung R.T. Intracerebroventricular injection of a neuropeptide Y-Y1 receptor agonist increases while BIBP3226, a Y1 antagonist, reduces the infarct volume following transient middle cerebral artery occlusion in rats. Neuroscience 116 1 (2003) 119-126
18. Chen S.H., Fung P.C., and Cheung R.T. Neuropeptide Y-Y1 receptor modulates nitric oxide level during stroke in the rat. Free Radical Biol. Med. 32 8 (2002) 776-784
19. Cheung R.T., and Cechetto D.F. Neuropeptide Y-Y1 receptor antisense oligodeoxynucleotide increases the infarct volume after middle cerebral artery occlusion in rats. Neuroscience 98 4 (2000) 771-777
20. Chronwall B.M., DiMaggio D.A., Massari V.J., Pickel V.M., Ruggiero D.A., and O'Donohue T.L. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 15 4 (1985) 1159-1181
21. Chronwall B.M., and Zukowska Z. Neuropeptide Y, ubiquitous and elusive. Peptides 25 3 (2004) 359-363 Review
22. Colmers W.F. Modulation of synaptic transmission in hippocampus by neuropeptide Y: presynaptic actions. Ann. NY Acad. Sci. 611 (1990) 206-218
23. Colmers W.F., and Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. 17 9 (1994) 373-379 Review
24. Coyle J.T. Neurotoxic action of kainic acid. J. Neurochem. 41 1 (1983) 1-11 Review
25. Domin H., Kajta M., and Śmiałowska M. Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures. Pharmacol. Rep. 58 6 (2006) 846-858
26. Doods H., Gaida W., Wieland H.A., Dollinger H., Schnorrenberg G., Esser F., Engel W., Eberlein W., and Rudolf K. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur. J. Pharmacol. 384 2-3 (1999) R3-R5
27. Dumont Y., Cadieux A., Doods H., Pheng L.H., Abounader R., Hamel E., Jacques D., Regoli D., and Quirion R. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br. J. Pharmacol. 129 6 (2000) 1075-1088
28. Dumont Y., Martel J.C., Fournier A., St-Pierre S., and Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol. 38 2 (1992) 125-167 Review
29. Edvinsson L. Neuropeptide Y and the cerebral circulation. In: Zukowska Z., and Feuerstein G.Z. (Eds). NPY Family of Peptides in Neurobiology, Cardiovascular and Metabolic Disorders: From Genes to Therapeutics (2006), Birkhauser Verlag, Switzerland 105-112
30. El Bahh B., Balosso S., Hamilton T., Herzog H., Beck-Sickinger A.G., Sperk G., Gehlert D.R., Vezzani A., and Colmers W.F. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur. J. Neurosci. 22 6 (2005) 1417-1430
31. Ferkany J.W., and Coyle J.T. Kainic acid selectively stimulates the release of endogenous excitatory acidic amino acids. J. Pharmacol. Exp. Ther. 225 2 (1983) 399-406
32. Fuhlendorff J., Gether U., Aakerlund L., Langeland-Johansen N., Thøgersen H., Melberg S.G., Olsen U.B., Thastrup O., and Schwartz T.W. [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc. Natl. Acad. Sci. USA 87 1 (1990) 182-186
33. Gariboldi M., Conti M., Cavaleri D., Samanin R., and Vezzani A. Anticonvulsant properties of BIBP3226, a non-peptide selective antagonist at neuropeptide Y Y1 receptors. Eur. J. Neurosci. 10 2 (1998) 757-759
34. Gobbi M., Monhemius R., Samanin R., Mennini T., and Vezzani A. Cellular localization of neuropeptide-Y receptors in the rat hippocampus: long-term effects of limbic seizures. Neuroreport 7 9 (1996) 1475-1480
35. Gray T.S., and Morley J.E. Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system. Life Sci. 38 5 (1986) 389-401
36. Greber S., Schwarzer C., and Sperk G. Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br. J. Pharmacol. 113 3 (1994) 737-740
37. Gundersen H.J.G., and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsci. 147 (1987) 229-263
38. Kajta M., Budziszewska B., and Lasoń W. Allopregnanolone attenuates kainate-induced toxicity in primary cortical neurons and PC12 neuronal cells. Pol. J. Pharmacol. 51 6 (1999) 531-534
39. Kajta M., and Lasoń W. Oestrogen effects on kainate-induced toxicity in primary cultures of rat cortical neurons. Acta Neurobiol. Exp. (Wars) 60 3 (2000) 365-369
40. Kajta M., Lasoń W., and Kupiec T. Effects of estrone on N-methyl-d-aspartic acid- and staurosporine-induced changes in caspase-3-like protease activity and lactate dehydrogenase-release: time and tissue-dependent effects in neuronal cultures. Neuroscience 123 (2004) 515-526
41. Kajta M., Trotter A., Lasoń W., and Beyer C. Effect of NMDA on staurosporine-induced activation of caspase-3 and LDH release in mouse neocortical and hippocampal cells. Brain Res. Dev. Brain Res. 160 1 (2005) 40-52
42. Kajta M., Domin H., Grynkiewicz G., and Lason W. Genistein inhibits glutamate-induced apoptotic processes in primary neuronal cell cultures: an involvement of aryl hydrocarbon receptor and estrogen receptor/glycogen synthase kinase-3beta intracellular signaling pathway. Neuroscience 145 2 (2007) 592-604
43. Klapstein G.J., and Colmers W.F. Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J. Neurophysiol. 78 (1997) 1651-1661
44. Kohler Ch., Eriksson L., Davies S., and Chan-Palay V. Neuropeptide Y innervation of the hippocampal region in the rat and monkey brain. J. Comp. Neurol. 244 (1986) 384-400
45. Kopp J., Xu Z.Q., Zhang X., Pedrazzini T., Herzog H., Kresse A., Wong H., Walsh J.H., and Hökfelt T. Expression of the neuropeptide Y Y1 receptor in the CNS of rat and of wild-type and Y1 receptor knock-out mice. Focus on immunohistochemical localization. Neuroscience 111 3 (2002) 443-532
46. Kuo L.E., Abe K., and Zukowska Z. Stress, NPY and vascular remodeling: Implications for stress-related diseases. Peptides 28 2 (2007) 435-440 Review. Erratum in: Peptides 2007, 28(4), 949. Abe, Ken [added]
47. 2+ currents mediated by neuropeptide Y Y2 receptors. J. Smooth Muscle Res. 35 5-6 (1999) 147-156
48. Longa E.Z., Weinstein P., Carlsson S., and Cummis R. Reversible middle cerebral artery occlusion without craniectomy in the rat. Stroke 20 (1989) 84-91
49. Malva J.O., Carvalho A.P., and Carvalho C.M. Kainate receptors in hippocampal CA3 subregion: evidence for a role in regulating neurotransmitter release. Neurochem. Int. 32 1 (1998) 1-6 Review
50. Marksteiner J., Lassmann H., Saria A., Humpel C., Meyer D.K., and Sperk G. Neuropeptide Levels after Pentylenetetrazol Kindling in the Rat. Eur. J. Neurosci. 2 1 (1990) 98-103
51. Marsh D.J., Baraban S.C., Hollopeter G., and Palmiter R.D. Role of the Y5 neuropeptide Y receptor in limbic seizures. Proc. Natl. Acad. Sci. USA 96 23 (1999) 13518-13523
52. McQuiston A.R., Petrozzino J.J., Connor J.A., and Colmers W.F. Neuropeptide Y1 receptors inhibit N-type calcium currents and reduce transient calcium increases in rat dentate granule cells. J. Neurosci. 16 4 (1996) 1422-1429
53. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., and Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50 1 (1998) 143-150 Review
54. Nanobashvili A., Woldbye D.P., Husum H., Bolwig T.G., and Kokaia M. Neuropeptide Y Y5 receptors suppress in vitro spontaneous epileptiform bursting in the rat hippocampus. Neuroreport 15 2 (2004) 339-343
55. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju S.M., Smulson M.E., Yamin T.-T., Yu V.L., and Miller D.K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376 (1995) 37-43
56. Ossowska K., Smiałowska M., Kuter K., Wierońska J., Zieba B., Wardas J., Nowak P., Dabrowska J., Bortel A., Biedka I., Schulze G., and Rommelspacher H. Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. Neuroscience 141 4 (2006) 2155-2165
57. Ossowska K., Wardas J., Smiałowska M., Kuter K., Lenda T., Wierońska J.M., Zieba B., Nowak P., Dabrowska J., Bortel A., Kwieciński A., and Wolfarth S. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease?. Eur. J. Neurosci. 22 6 (2005) 1294-1304
58. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. second ed. (1986), Academic Press, San Diego, CA
59. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., and Doods H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 271 2-3 (1994) R11-R13
60. Schwarzer C., Kirchmair E., and Sperk G. Metabotropic glutamate receptors mediate activation of NPY-Y2 receptor expression in the rat dentate gyrus. Neuroreport 9 10 (1998) 2347-2351
61. Schwarzer C., Sperk G., Samanin R., Rizzi M., Gariboldi M., and Vezzani A. Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Brain Res. Brain Res. Rev. 22 1 (1996) 27-50 Review
62. Shih Y.H., Chein Y.C., Wang J.Y., and Fu Y.S. Ursolic acid protects hippocampal neurons against kainate-induced excitotoxicity in rats. Neurosci. Lett. 362 (2004) 136-140
63. Shih Y.H., Wu S.L., Chiou W.F., Ku H.H., Ko T.L., and Fu Y.S. Protective effects of tetramethylpyrazine on kainate-induced excitotoxicity in hippocampal culture. Neuroreport 13 (2002) 515-519
64. Silva A.P., Carvalho A.P., Carvalho C.M., and Malva J.O. Modulation of intracellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyrus. J. Neurochem. 79 2 (2001) 286-296
65. Silva A.P., Cavadas C., and Grouzmann E. Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin. Chim. Acta 326 1-2 (2002) 3-25 Review
66. Silva A.P., Pinheiro P.S., Carvalho A.P., Carvalho C.M., Jakobsen B., Zimmer J., and Malva J.O. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J. 17 9 (2003) 1118-1120
67. Silva A.P., Xapelli S., Grouzmann E., and Cavadas C. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr. Drug Targets CNS Neurol. Disord. 4 4 (2005) 331-347 Review
68. Silva A.P., Xapelli S., Pinheiro P.S., Ferreira R., Lourenço J., Cristóvão A., Grouzmann E., Cavadas C., Oliveira C.R., and Malva J.O. Up-regulation of neuropeptide Y levels and modulation of glutamate release through neuropeptide Y receptors in the hippocampus of kainate-induced epileptic rats. J. Neurochem. 93 1 (2005) 163-170
69. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., and Sharp F.R. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10 (1990) 290-293
70. Śmiałowska M., Wierońska J.M., and Szewczyk B. Neuroprotective effect of NPY on kainate neurotoxicity in the hippocampus. Pol. J. Pharmacol. 55 6 (2003) 979-986
71. Thiriet N., Deng X., Solinas M., Ladenheim B., Curtis W., Goldberg S.R., Palmiter R.D., and Cadet J.L. Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J. Neurosci. 25 22 (2005) 5273-5279
72. Vezzani A., Sperk G., and Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 22 1 (1999) 25-30 Review
73. Wahlestedt C., Edvinsson L., Ekblad E., and Håkanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J. Pharmacol. Exp. Ther. 234 3 (1985) 735-741
74. Wahlestedt C., and Reis D.J. Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets?. Annu. Rev. Pharmacol. Toxicol. 33 (1993) 309-352 Review
75. Wang Q., Yu S., Simonyi A., Sun G.Y., and Sun A.Y. Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol. Neurobiol. 31 1-3 (2005) 3-16 Review
76. Wieland H.A., Engel W., Eberlein W., Rudolf K., and Doods H.N. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J. Pharmacol. 125 3 (1998) 549-555
77. Woldbye D.P., Larsen P.J., Mikkelsen J.D., Klemp K., Madsen T.M., and Bolwig T.G. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat. Med. 3 7 (1997) 761-764
78. Wu Y.F., and Li S.B. Neuropeptide Y expression in mouse hippocampus and its role in neuronal excitotoxicity. Acta Pharmacol. Sin. 26 1 (2005) 63-68
79. Xapelli S., Bernardino L., Ferreira R., Grade S., Silva A.P., Salgado J.R., Cavadas C., Grouzmann E., Paulsen F.R., Jakobsen B., Oliveira C.R., Zimmer J., and Malva J.O. Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur. J. Neurosci. 27 8 (2008) 2089-2102
80. Xapelli S., Silva A.P., Ferreira R., and Malva J.O. Neuropeptide Y can rescue neurons from cell death following the application of an excitotoxic insult with kainate in rat organotypic hippocampal slice cultures. Peptides 28 2 (2007) 288-294
81. Zukowska Z., Pons J., Lee E.W., and Li L. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system?. Can J. Physiol. Pharmacol. 81 2 (2003) 89-94 Review